This page lists the SEC filings reported by Broadfin Capital, LLC.
| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G/A | 2021-01-04 | Broadfin Capital, LLC | LA JOLLA PHARMACEUTICAL CO | 0 | 0.0% | EDGAR |
| SC 13G/A | 2021-01-04 | Broadfin Capital, LLC | Eiger BioPharmaceuticals, Inc. | 0 | 0.0% | EDGAR |
| SC 13D/A | 2020-06-23 | Broadfin Capital, LLC | STRATA Skin Sciences, Inc. | 1,529,392 | 4.5% | EDGAR |
| SC 13G/A | 2020-02-25 | Broadfin Capital, LLC | Teligent, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2020-02-14 | Broadfin Capital, LLC | Neos Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2020-02-13 | Broadfin Capital, LLC | Recro Pharma, Inc. | 721,073 | 3.2% | EDGAR |
| SC 13G/A | 2020-02-13 | Broadfin Capital, LLC | CATALYST PHARMACEUTICALS, INC. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2020-02-13 | Broadfin Capital, LLC | Retrophin, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2020-02-13 | Broadfin Capital, LLC | Eiger BioPharmaceuticals, Inc. | 1,236,368 | 5.0% | EDGAR |
| SC 13G/A | 2020-02-13 | Broadfin Capital, LLC | Adamas Pharmaceuticals Inc | 0 | 0.0% | EDGAR |
| SC 13G/A | 2020-02-13 | Broadfin Capital, LLC | Aclaris Therapeutics, Inc. | 1,888,039 | 4.6% | EDGAR |
| SC 13G/A | 2020-02-13 | Broadfin Capital, LLC | CATALYST PHARMACEUTICALS, INC. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2020-02-13 | Broadfin Capital, LLC | Strongbridge Biopharma plc | 600,000 | 1.1% | EDGAR |
| SC 13G/A | 2020-02-13 | Broadfin Capital, LLC | TELIGENT INC | 0 | 0.0% | EDGAR |
| SC 13G/A | 2020-02-13 | Broadfin Capital, LLC | Sierra Oncology, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2020-02-13 | Broadfin Capital, LLC | LA JOLLA PHARMACEUTICAL CO | 2,688,068 | 9.9% | EDGAR |
| SC 13G/A | 2020-02-13 | Broadfin Capital, LLC | AVADEL PHARMACEUTICALS PLC | 1,029,012 | 2.8% | EDGAR |
| SC 13G/A | 2020-02-13 | Broadfin Capital, LLC | ADMA BIOLOGICS, INC. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2020-02-13 | Broadfin Capital, LLC | Zyla Life Sciences | 0 | 0.0% | EDGAR |
| SC 13D/A | 2020-01-23 | Broadfin Capital, LLC | STRATA Skin Sciences, Inc. | 2,170,757 | 6.4% | EDGAR |
- Form 13F-HR
- The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
- Form SC 13D/G
- Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
- Form 3, 4, and 5
- Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.